RxDoctor Payments Data

James Neiner, MD

MOHS-Micrographic Surgery · San Antonio, TXNPI 1619170024

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.8% of the total across 173 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 30.3% of the total.

$3,906in general payments, 2019–2025

Across 173 payments — averaging $22.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Regeneron Healthcare Solutions, Inc.$311
  • Lilly USA, LLC$299
  • E.r. Squibb & Sons, L.L.C.$291
  • Organon$214
  • Johnson & Johnson$214
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,70295%
  • Education$2055%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,906 in reported general payments places this provider in the 65th percentile of 109 mohs-micrographic surgery providers in Texas.

See all mohs-micrographic surgery providers in Texas

Medicare billing

Part B allowed, 2024
$688,124
Medicare patients
596
Services billed
3,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluorouracil35$2,454
Doxycycline Hyclate34$2,073
Clobetasol Propionate32$1,392
Desonide22$1,045
Ketoconazole51$862
Mupirocin93$737
Cephalexin83$656
Triamcinolone Acetonide60$599
Clindamycin Phosphate11$409

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →